Fosamprenavir Expanded Access
Phase 4
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Registration Number
- NCT00240552
- Lead Sponsor
- ViiV Healthcare
- Brief Summary
This open-label study will enable HIV-infected adults with limited treatment options to receive fosamprenavir until commercial supplies are available in Switzerland.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 85
Inclusion Criteria
-
HIV-1 infected subjects.
-
Subjects must belong to one of the following populations:
- Subjects with limited treatment options due to viral resistance, interactions, or tolerability issues with other antiretroviral drugs.
- Subjects who already receive amprenavir (Agenerase®)
- Subjects for whom once daily dosing of antiretroviral therapy is indicated, including, once daily dosing with fosamprenavir/ritonavir.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of fosamprenavir resistance in HIV patients with limited treatment options?
How does fosamprenavir compare to standard-of-care protease inhibitors in virologic suppression for multi-drug resistant HIV?
Which biomarkers correlate with long-term CD4+ T cell count stability in fosamprenavir-treated HIV patients?
What are the most common adverse events associated with fosamprenavir regimens in Phase IV HIV trials?
How do fosamprenavir-ritonavir combinations influence viral load reduction compared to boosted darunavir in salvage therapy?
Trial Locations
- Locations (1)
GSK Investigational Site
🇨🇭Zurich, Switzerland